These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1558 related articles for article (PubMed ID: 26545340)

  • 1. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects.
    Tian S; Wang B; Ding Y; Zhang Y; Yu P; Chang YZ; Gao G
    Biomed Pharmacother; 2024 Oct; 179():117419. PubMed ID: 39245001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Iron Metabolism Dysfunction in Parkinson's Disease.
    Jiang H; Wang J; Rogers J; Xie J
    Mol Neurobiol; 2017 May; 54(4):3078-3101. PubMed ID: 27039308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases.
    Wojtunik-Kulesza K; Oniszczuk A; Waksmundzka-Hajnos M
    Biomed Pharmacother; 2019 Mar; 111():1277-1289. PubMed ID: 30841441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycation in Parkinson's disease and Alzheimer's disease.
    Vicente Miranda H; El-Agnaf OM; Outeiro TF
    Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.
    Altamura S; Muckenthaler MU
    J Alzheimers Dis; 2009; 16(4):879-95. PubMed ID: 19387120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer's, and Parkinson's Diseases.
    Raha AA; Biswas A; Henderson J; Chakraborty S; Holland A; Friedland RP; Mukaetova-Ladinska E; Zaman S; Raha-Chowdhury R
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain iron metabolism and its perturbation in neurological diseases.
    Crichton RR; Dexter DT; Ward RJ
    J Neural Transm (Vienna); 2011 Mar; 118(3):301-14. PubMed ID: 20809066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics.
    Davies KM; Mercer JF; Chen N; Double KL
    Clin Sci (Lond); 2016 Apr; 130(8):565-74. PubMed ID: 26957644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease.
    Jiang T; Sun Q; Chen S
    Prog Neurobiol; 2016 Dec; 147():1-19. PubMed ID: 27769868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?
    Jodeiri Farshbaf M; Ghaedi K
    Biometals; 2017 Feb; 30(1):1-16. PubMed ID: 27853903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases.
    Srivastava S; Haigis MC
    Curr Pharm Des; 2011; 17(31):3418-33. PubMed ID: 21902666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.
    Loeffler DA; Connor JR; Juneau PL; Snyder BS; Kanaley L; DeMaggio AJ; Nguyen H; Brickman CM; LeWitt PA
    J Neurochem; 1995 Aug; 65(2):710-24. PubMed ID: 7616227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metals in Alzheimer's and Parkinson's diseases.
    Barnham KJ; Bush AI
    Curr Opin Chem Biol; 2008 Apr; 12(2):222-8. PubMed ID: 18342639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
    Apostolakis S; Kypraiou AM
    Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.